# Clinical Trial to Investigate the Safety, Tolerability and Pharmacokinetics and Pharmacodynamics of JP-1366 Oral Administration in Healthy Male Subjects

> **NCT03383042** · PHASE1 · COMPLETED · sponsor: **Jeil Pharmaceutical Co., Ltd.** · enrollment: 115 (actual)

## Conditions studied

- Anti-Ulcer Agents

## Interventions

- **DRUG:** Cohort 1 (JP-1366 A mg)
- **DRUG:** Cohort 2 (JP-1366 B mg)
- **DRUG:** Cohort 3 (JP-1366 C mg)
- **DRUG:** Cohort 4 (JP-1366 D mg)
- **DRUG:** Cohort 5 (JP-1366 E mg)
- **DRUG:** Cohort 6 (JP-1366 F mg)
- **DRUG:** Cohort 7 (JP-1366 G mg)
- **DRUG:** Cohort 8 (JP-1366 H mg)
- **DRUG:** Cohort 9 (JP-1366 I mg)

## Key facts

- **NCT ID:** NCT03383042
- **Lead sponsor:** Jeil Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-12-22
- **Primary completion:** 2018-11-23
- **Final completion:** 2019-04-05
- **Target enrollment:** 115 (ACTUAL)
- **Last updated:** 2019-04-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03383042

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03383042, "Clinical Trial to Investigate the Safety, Tolerability and Pharmacokinetics and Pharmacodynamics of JP-1366 Oral Administration in Healthy Male Subjects". Retrieved via MORVS 2026-10-17 from https://api.morvs.ai/clinical/NCT03383042. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*